About Our Service
Neuroblastoma is a rare type of cancer that almost always occurs in infants and young children. One in 7,000 kids will be diagnosed with neuroblastoma each year in the U.S. A related rare pediatric cancer is medulloblastoma, which accounts for 15 to 20 percent of all pediatric brain tumors.
The Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) is a group of universities and children’s hospitals that offer a nationwide network of childhood cancer clinical trials. The NMTRC is led by our team at Helen DeVos Children’s Hospital.
The trials are based on the research from a group of closely collaborating investigators who are developing new therapies for these high-risk children's cancers.